Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immutep Limited
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
November 8, 2026
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
November 5, 2026
Immutep Quarterly Activities Report Q1 FY27
October 29, 2026
Immutep Receives A$2.16 million French R&D Tax Incentive
October 28, 2026
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
October 23, 2026
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
October 19, 2026
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
October 14, 2026
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 13, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 30, 2026
Change to American Depositary Share Ratio
September 21, 2026
1
2
Next Page
→